Skip to main content
Fig. 1 | Translational Medicine Communications

Fig. 1

From: Biomarkers in immune checkpoint inhibition therapy for cancer patients: what is the role of lymphocyte subsets and PD1/PD-L1?

Fig. 1

Timeline figure showing the milestones in the history and development of cancer immunotherapies. FDA (Food and Drug Association); IL-2 (Interleukin 2); PD-1 (Programmed Death receptor-1); PD-L1 (Programmed Death receptor Ligand-1); IHC (Immunohistochemistry). CTLA-4 (Cytotoxic T-lymphocyte associated protein-4); MSI-high (microsatellite instable-high) Additional file 1

Back to article page

Translational Medicine Communications

ISSN: 2396-832X

Contact us